The American Cancer Society National Lung Cancer Roundtable strategic plan: Challenges in clinical guideline recommendations for biomarker testing in lung cancer.

doi:10.1002/cncr.70384

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The American Cancer Society National Lung Cancer Roundtable strategic plan: Challenges in clinical guideline recommendations for biomarker testing in lung cancer.

Cancer - 15 May 2026

Patel Shetal A, Heald Jonathan L, Nead Michael, Singer Bart, Eapen George A, Farjah Farhood, Kelly Karen, Kim Edward S, Mani Haresh, Osarogiagbon Raymond U, Pastis Nicholas J, Pannu Jasleen K, Scholl Lynette, Sears Catherine R, Silvestri Gerard A, Smith Robert A, Suh Robert D, Wood Douglas, DiJulio Terri A, Johnson Bruce E, Wistuba Ignacio I, Rivera M Patricia

Abstract excerpt

Molecular profiling has revolutionized the diagnosis and management of patients with non-small cell lung cancer (NSCLC), enabling personalized treatment approaches that have significantly improved patient outcomes. Identifying specific gene mutations and protein expression profiles guides therapeutic decisions and has become standard in the management of patients with NSCLC. Multiple organizations have published...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Carcinoma, Non-Small-Cell Lung

Share to Lung Neoplasms

Share to Mutation

Share to Practice Guidelines as Topic

Share to Precision Medicine

Share to Societies, Medical

Share to United States

Source

Open in PubMed

Identifiers

PMID: 42118609
DOI: 10.1002/cncr.70384

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The American Cancer Society National Lung Cancer Roundtable strategic plan: Challenges in clinical guideline recommendations for biomarker testing in lung cancer.PMID 42118609Read ↗

Consensus Recommendations for Optimizing Biomarker Testing to Identify and Treat Advanced EGFR-Mutated Non-Small-Cell Lung CancerSemantic proximity Read ↗

Biomarkers and molecular profiling in non-small cell lung cancer: an expanding role and its managed care implications.Semantic proximity Read ↗

Current and future trends in non-small cell lung cancer biomarker testing: The American experience.Semantic proximity Read ↗

Biomarker Testing for Actionable Alterations in NSCLC-Perspectives from US-Based Academic and Community Oncologists: A Podcast.Semantic proximity Read ↗

The evolving landscape of biomarker testing for non-small cell lung cancer in Europe.Semantic proximity Read ↗

The rapidly evolving landscape of biomarker testing in non-small cell lung cancer.Semantic proximity Read ↗

Biomarker testing in non-small cell lung cancer: a clinician's perspective.Semantic proximity Read ↗

Molecular Pathology of Lung Cancer.Semantic proximity Read ↗

Prognostic and predictive biomarkers in non-small cell lung carcinoma.Semantic proximity Read ↗

What, When, and How of Biomarker Testing in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology.Semantic proximity Read ↗

Molecular Testing in Lung Cancer: Recommendations and Update.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.